Intervention

Rapamycin

ClinicalTrials.gov intervention label

Clinical trials13

Recruiting1

Common conditions15

Lead sponsors shown12

Clinical trials

13 shown

Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis ComplexNCT05534672 · 2023-01-23

A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)NCT06682767 · 2026-11-01

NOT_YET_RECRUITING

Rapamycin - Effects on Alzheimer's and Cognitive HealthNCT04629495 · 2021-08-11

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsNCT04987463 · 2021-05-07

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM PathwayNCT04736589 · 2021-02-02

NOT_YET_RECRUITING

Aging Mammary Stem Cells and Breast Cancer PreventionNCT02642094 · 2016-07-01

Minimal Islet Transplant at Diabetes OnsetNCT02505893 · 2015-04-01

Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous SclerosisNCT03140449 · 2013-09-05

Topical Rapamycin to Erase Angiofibromas in TSCNCT01526356 · 2012-05-01

Proleukin and Rapamune in Type 1 DiabetesNCT00525889 · 2007-08-01

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast CancerNCT00411788 · 2006-12-01

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMASNCT00126672 · 2005-12-20

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas RecipientsNCT00533442 · 2000-09-01

Common conditions

Breast Cancer2 Diabetes Mellitus, Type 12 Tuberous Sclerosis2 Tuberous Sclerosis Complex2 Alzheimer Disease1 Angiofibromas1 APOE 41 Cancer of Breast1 Cerebral Blood Flow1 Facial Angiofibroma1 Kidney Angiomyolipoma1 Lymphangioleimyomatosis1 Mild Cognitive Impairment1 Nonmalignant Neoplasm1 Type 1 Diabetes1

Leading sponsors

Katarzyna Kotulska2 Cedars-Sinai Medical Center1 Dana-Farber Cancer Institute1 LuZhe Sun1 National Institute of Allergy and Infectious Diseases (NIAID)1 National Taiwan University Hospital1 Ospedale San Raffaele1 Peking Union Medical College1 The University of Texas Health Science Center at San Antonio1 The University of Texas Health Science Center, Houston1 University of Miami1 Yale University1

Trial status mix

COMPLETED7

NOT_YET_RECRUITING2

ACTIVE_NOT_RECRUITING1

RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

PHASE29

PHASE34

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.